# US 2022/0016091 A1 · Methods of increasing tonic inhibition and treating secondary insomnia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016091 A1
- Document ID: US20220016091A1
- Status: Published application
- Kind: A1
- Application number: 17/490,650
- Filed: 2021-09-30
- Published: 2022-01-20
- Earliest claimed: 2014-06-06
- Assignees: Ovid Therapeutics Inc.
- Applicants: Ovid Therapeutics Inc.
- Inventors: Matthew During
- Web page: https://patentgrep.com/patent/US20220016091A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof.

## Claims

### Claim 1

A method of treating Dementia with Lewy Bodies comprising administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 2

A method of treating Dementia with Lewy Bodies comprising administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof and a compound selected from the group consisting of memantine, galantamine, donepezil and rivastigmine.

### Claim 3 (depends on 2)

The method of claim 2, wherein memantine or a pharmaceutically acceptable salt thereof is administered at a dosage of between about 1 mg to about 30 mg.

### Claim 4 (depends on 2)

The method of claim 2, wherein memantine or a pharmaceutically acceptable salt thereof is administered at a dosage of about 5 mg or 10 mg.

### Claim 5 (depends on 2)

The method of claim 2, wherein memantine or a pharmaceutically acceptable salt thereof is administered at a dosage of about 7 mg, 14 mg, 21 mg, or 28 mg in a conventional release dosage form or an extended release dosage form.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is administered 0.1 mg to 50 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient is administered 2.5 mg to 30 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the patient is administered a dose of gaboxadol or a pharmaceutically acceptable salt thereof ranging from 0.1 mg/kg to 3.0 mg/kg.

### Claim 9 (depends on 2)

The method of claim 2, wherein the patient is administered 1.0 mg to 30 mg galantamine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 2)

The method of claim 2, wherein the patient is administered extended release galantamine or a pharmaceutically acceptable salt thereof at a dosage of 8 mg, 16 mg, or 24 mg.

### Claim 11 (depends on 2)

The method of claim 2, wherein the patient is administered 1.0 mg to 30 mg donepezil or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 2)

The method of claim 2, wherein the patient is administered donepezil or a pharmaceutically acceptable salt thereof at a dosage of 5 mg, 10 mg, or 23 mg.

### Claim 13 (depends on 2)

The method of claim 2, wherein the patient is administered 1.0 mg to 20 mg rivastigmine or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 2)

The method of claim 2, wherein the patient is administered rivastigmine or a pharmaceutically acceptable salt thereof at a dosage of 4.6 mg, 9.5 mg, or 13.3 mg.

### Claim 15 (depends on 2)

The method of claim 2, wherein the patient is administered an oral solution of rivastigmine or a pharmaceutically acceptable salt thereof at a dosage of 1 mg/ml.

### Claim 16 (depends on 1)

The method of claim 1, wherein the patient is administered a subtherapeutic dosage of memantine or a pharmaceutically acceptable salt thereof, galantamine or a pharmaceutically acceptable salt thereof, donepezil or a pharmaceutically acceptable salt thereof, or rivastigmine or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the patient is administered about 1 mg to about 20 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the patient is administered about 1 mg to about 15 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the patient is administered about 1 mg to about 10 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the patient is administered about 5 mg or about 10 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The method of claim 1, further comprising administering memantine or a pharmaceutically acceptable salt thereof.
